Reply to Matonti et al.

Sir, We thank Dr Matonti et al1 for their interest in and comments on our recent article.2 We agree that in our study we should have been waiting longer to definitely assess the effects of autologous plasmin enzyme (APE) in patients with vitreomacular traction syndrome. In fact, although we could not ascertain if a greater time gap could have influenced the rate of posterior vitreous detachment occurrence, as Dr Matonti et al correctly pointed out, we remarked that the single injection appeared as a useful tool in vitreoretinal surgery because of obtaining an easier-to-peel posterior hyaloid.3 However, as per our ethical committee-approved protocol (reported in the Methods section), and due to medico-legal reasons, we were allowed to perform just one single intravitreal injection for each study patient, with a 24-h waiting time before vitrectomy. This, together with the impossibility (per protocol) to re-inject patients with APE, should be acknowledged as the limitation of our study.